Although the primary endpoint, after 52 weeks in subjects treated with pioglitazone, did not reach statistical significance for histological improvements in NASH (46) , secondary endpoint scores were met, as in reduction in steatosis, lobular inflammation, and reduction in the non-alcoholic fatty liver disease.
← all excerpts
The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.
1
—
—